What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
Multiple myeloma, Internal medicine, Surgery, Oncology and Bortezomib are his primary areas of study.
His study in Multiple myeloma is interdisciplinary in nature, drawing from both Dexamethasone and Transplantation.
His Internal medicine research incorporates elements of Gastroenterology and Pathology.
In his research on the topic of Surgery, Placebo is strongly related with Ixazomib.
His research in Oncology intersects with topics in Survival analysis, Retrospective cohort study, Minimal Residual Disease Negativity and Daratumumab.
His Carfilzomib study in the realm of Bortezomib connects with subjects such as Peripheral neuropathy.
His most cited work include:
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (828 citations)
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma (818 citations)
- Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma (795 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Multiple myeloma, Internal medicine, Oncology, Surgery and Transplantation.
His research on Multiple myeloma often connects related areas such as Dexamethasone.
His Dexamethasone research is multidisciplinary, incorporating elements of Placebo and Adverse effect.
Philippe Moreau combines topics linked to Gastroenterology with his work on Internal medicine.
His work investigates the relationship between Oncology and topics such as Immunology that intersect with problems in Cancer research.
His Transplantation study combines topics in areas such as Maintenance therapy, Stem cell, Fludarabine and Cumulative incidence.
He most often published in these fields:
- Multiple myeloma (61.68%)
- Internal medicine (59.63%)
- Oncology (31.96%)
What were the highlights of his more recent work (between 2017-2021)?
- Multiple myeloma (61.68%)
- Internal medicine (59.63%)
- Oncology (31.96%)
In recent papers he was focusing on the following fields of study:
His main research concerns Multiple myeloma, Internal medicine, Oncology, Dexamethasone and Lenalidomide.
His studies in Multiple myeloma integrate themes in fields like Cancer research, Clinical trial, Refractory and Transplantation.
His Internal medicine study often links to related topics such as Gastroenterology.
Philippe Moreau has included themes like Proteasome inhibitor, Regimen and Ixazomib in his Oncology study.
Within one scientific family, he focuses on topics pertaining to Progression-free survival under Dexamethasone, and may sometimes address concerns connected to Melphalan.
His studies deal with areas such as Thalidomide, Survival rate, Newly diagnosed, Minimal residual disease and Clinical endpoint as well as Lenalidomide.
Between 2017 and 2021, his most popular works were:
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. (282 citations)
- Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study (261 citations)
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. (191 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
Philippe Moreau spends much of his time researching Multiple myeloma, Internal medicine, Lenalidomide, Clinical trial and Bortezomib.
His study in Multiple myeloma is interdisciplinary in nature, drawing from both Cancer research, Refractory, Transplantation and Intensive care medicine.
His work deals with themes such as Maintenance therapy, Thalidomide and Regimen, which intersect with Transplantation.
He has researched Internal medicine in several fields, including Gastroenterology and Oncology.
The various areas that he examines in his Lenalidomide study include Survival rate and Minimal residual disease.
Philippe Moreau works mostly in the field of Bortezomib, limiting it down to topics relating to Standard treatment and, in certain cases, Discontinuation and Heart failure, as a part of the same area of interest.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
